All In Biotech

Drug Trial Radar · NCT05628389

Phone Enabled Implementation of Cessation Support

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Aug 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The tobacco use burden in Lebanon is exceptionally high: 35% of adults are current cigarette smokers and 39% are current waterpipe smokers. Although the World Health Organization endorses evidence-based interventions for population-level tobacco dependence treatment, recommended treatments are not integrated as a routine part of primary care in Lebanon, as is the case in other low-resource settings. The objective of this proposal is to evaluate the comparative effectiveness of promising multi-component interventions for implementing evidence-based cessation treatment in Lebanon's national system of primary health care centers.

Conditions

  • Smoking Cessation

Interventions

  • Educational materialsBehavioral

    Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.

  • Phone counselingBehavioral

    Cessation counseling to address insufficient patient self-efficacy and motivation.

  • Nicotine Replacement TherapyDrug

    Nicotine patches to address nicotine withdrawal symptoms in patients.

  • Provider trainingBehavioral

    Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.

  • Electronic remindersBehavioral

    Electronic reminders to address the lack of integration of AAA/AAC into practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 7-day smoking abstinenceTime frame: 6 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • American University of Beirut Medical Center

    Beirut, Lebanon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.